GlassScriptPhysician profile
Heather Mednansky
NPI 1336664184
$3,289.73
in general payments reported to CMS, 2019-2025
30 companies · $539 in 2025
The $539 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,335 · 2022: $410 · 2023: $510 · 2024: $495 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.07 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $816.01 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $741.82 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $436.50 | 2021-2025 | |
| Pfizer INC. | $206.90 | 2021-2025 | |
| Medtronic, INC. | $124.57 | 2022-2024 | Minimed 780g |
| Edwards Lifesciences Corporation | $92.81 | 2021-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $70.12 | 2025 | Proclaim, Jot Dx |
| Janssen Pharmaceuticals, INC | $64.48 | 2021-2022 | |
| Exact Sciences Corporation | $64.19 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $58.08 | 2024 | Veozah |
| Boston Scientific Corporation | $57.81 | 2021-2025 | General - Therapies |
| Takeda Pharmaceuticals U.S.A., INC. | $53.26 | 2022 | |
| Currax Pharmaceuticals LLC | $52.75 | 2023-2025 | Contrave, Nexletol |
| Cleerly, INC. | $49.86 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Lilly USA, LLC | $45.26 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $45.20 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $43.74 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lucid Diagnostics INC. | $38.34 | 2023 | |
| Amgen INC. | $30.78 | 2021 | |
| Nevro Corp. | $26.14 | 2023 | Senza |
| Impulse Dynamics (USA) INC. | $24.54 | 2024 | Optimizer |
| Mannkind Corporation | $23.93 | 2023 | Afrezza |
| Alexion Pharmaceuticals, INC. | $22.63 | 2022 | |
| Teleflex LLC | $16.78 | 2025 | Barrigel |
| Impel Pharmaceuticals INC. | $16.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.18 | 2023 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $14.34 | 2025 | Ajovy |
| Paratek Pharmaceuticals, INC. | $13.05 | 2023 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $12.29 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.09 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Mednansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.